CNMDNYSEElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
CONMED Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$46.05−0.67 (-1.43%)
Close on Oct 19, 2026
- Market cap
- $1.39B
- P/E (TTM)
- 30.5
- Dividend yield
- 1.30%
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
54.6%+1.2 pts over 5 years
Operating margin
7.5%+2.1 pts over 5 years
Net margin
3.4%+2.3 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +5.2% | +9.6% | +9.8% | +6.7% | |
| Gross profit | +2.4% | +9.5% | +10.3% | +7.0% | |
| Operating income | -48.8% | +13.6% | +17.4% | +7.2% | |
| Net income | -64.5% | – | +37.7% | +4.4% | |
| EPS, diluted | -64.5% | – | +36.4% | +3.3% | |
| Free cash flow | -2.0% | +135.3% | +24.0% | +15.4% | |
| Dividend per share | -25.0% | -9.1% | -5.6% | -2.8% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 2.5% | 1.3% | 4.7% | |
| Return on assets | 1.2% | 0.5% | 2.0% | |
| Current ratio | 2.90 | 2.19 | 2.14 | |
| Debt to equity | 0.86 | 1.06 | 0.81 | |
| Interest coverage | 2.5× | 1.0× | 3.3× | |
| Inventory turnover | 2.6× | 2.2× | 1.8× | |
| Capex to revenue | 1.9% | 1.5% | 1.4% | |
| Diluted shares | 28M | 29M | 31M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Conmed generated $608.14M from operations and spent $209.69M on capital expenditure, dividends and share buybacks. 42% of that went back into the business.
Generated
$608.14M
Used
$209.69M
Capital expenditure$88.57M42%Dividends$121.12M58%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin3.4%
×Asset turnover0.59×
×Equity multiplier2.32×
=Return on equity, FY20254.7%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 3.4% | 0.59× | 2.32× | 4.7% |
| FY2024 | 10.1% | 0.57× | 2.56× | 14.7% |
| FY2023 | 5.2% | 0.54× | 2.91× | 8.2% |
| FY2022 | -7.7% | 0.51× | 2.65× | -10.5% |
| FY2021 | 6.2% | 0.57× | 2.35× | 8.4% |
| FY2020 | 1.1% | 0.49× | 2.48× | 1.3% |
| FY2019 | 3.0% | 0.61× | 2.29× | 4.2% |
| FY2018 | 4.8% | 0.63× | 2.11× | 6.3% |
| FY2017 | 7.0% | 0.59× | 2.22× | 9.2% |
| FY2016 | 1.9% | 0.63× | 2.09× | 2.5% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
6of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero$47.06M
- Cash generatingOperating cash flow above zero$170.69M
- Return on assets improvedROA up on the prior year5.8% → 2.0%
- Earnings backed by cashOperating cash flow above net income$170.69M vs $47.06M
- Less leverageLong-term debt to assets fell39.2% → 35.9%
- Better liquidityCurrent ratio rose2.30 → 2.14
- No dilutionShare count did not rise31M → 31M
- Gross margin improvedGross margin up on the prior year56.08% → 54.59%
- More efficientAsset turnover rose0.57 → 0.60